Get the app
USHealthcare

Enovis Corp (ENOV)

US · Healthcare · Medical Devices

$17.80-4.61%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$582.8M
Revenue YoY
+3.2%
Net profit
$-1.2M
EPS
$0.76
EPS estimate
$0.79
Net margin
-0.2%

EPS came in at 0.76 against a street estimate of 0.79 — a miss of 3.8%.

Key statistics

Market cap
$1.08B
Forward P/E
4.6
P/B
0.70
Book value
$25.61
EPS (TTM)
$-20.04
52-week high
$34.28
52-week low
$17.30
50-day MA
$24.93
200-day MA
$24.38
Beta
1.43

Analyst view

Analysts rate Enovis Corp a strong buy (10 buy, 1 hold, 0 sell out of 11) with an average price target of $38.33.

Shareholding

Insiders
1.64%
Institutions
125.08%

Largest institutional holders

FundStake
BlackRock Inc17.23%
American Century Companies Inc10.59%
Vanguard Portfolio Management, LLC6.60%
Vanguard Capital Management, LLC4.43%
Rubric Capital Management LP4.25%
State Street Corp4.17%
Davenport & Company LLC4.06%
Hood River Capital Management LLC3.05%

Recent filings & reports

DocumentDate
Reg FD disclosure · Q3 2026
ENOVIS CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • Deal size (enterprise value): €155,000,000 • Upfront cash payment to shareholders: €176,000
2026-09-01
Quarterly report · Q3 2026
ENOVIS CORPORATION – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net Sales Q2 2026: $582.8 million (up 3.2% vs. $564.5 million in Q2 2025) • Net Sales H
2026-08-06
Results announced · Q3 2026
ENOVIS CORPORATION – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Net Sales: $582.8 million, up 3% reported / 5% organic year-over-year • Q2
2026-08-06
Board / officer change · Q2 2026
ENOVIS CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 19, 2026 • 3,650,000 additional shares authorized for issuance unde
2026-05-19
Quarterly report · Q2 2026
ENOVIS CORPORATION – Q1 2026 10-Q SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Net sales Q1 2026: $589.2 million vs. $558.8 million Q1 2025
2026-05-07
Results announced · Q2 2026
ENOVIS CORPORATION Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q1 2026 net sales: $589.2 million, up 5% reported basis, up 3% organic basis vs. Q1 2
2026-05-07
Proxy statement · Q2 2026
ENOVIS CORPORATION PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect 10 directors to the Board (Sharon Wienbar, Damien McD
2026-04-06
Annual report FY2025
ENOVIS CORPORATION – FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market capitalization (as of July 4, 2025): $1.91 billion • Outstandi
2026-02-26

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Enovis Corp — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.